Codexis Revenue and Competitors

Location

$162M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Codexis's estimated annual revenue is currently $101.3M per year.(i)
  • Codexis received $25.3M in venture funding in April 2017.
  • Codexis's estimated revenue per employee is $379,363
  • Codexis's total funding is $162M.
  • Codexis's current valuation is $1.7B. (January 2022)

Employee Data

  • Codexis has 267 Employees.(i)
  • Codexis grew their employee count by -21% last year.

Codexis's People

NameTitleEmail/Phone
1
CEO and PresidentReveal Email/Phone
2
Chief Legal and Compliance Officer, General CounselReveal Email/Phone
3
Chief Legal and Compliance Officer, General Counsel and SecretaryReveal Email/Phone
4
Sr. VP, Strategic DevelopmentReveal Email/Phone
5
VP, Corporate LawReveal Email/Phone
6
VP FinanceReveal Email/Phone
7
SVP & General Manager, Performance EnzymesReveal Email/Phone
8
SVP, ResearchReveal Email/Phone
9
SVP, Product OperationsReveal Email/Phone
10
VP Information TechnologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.2M225%N/AN/A
Add Company

What Is Codexis?

Codexis, Inc. is a leading protein engineering company applying innovative technologies to Unlock the Power of Proteins. Our proprietary CodeEvolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. Codexis revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. You get precisely the protein you need for the job you want it to do. Guided by proprietary artificial intelligence software and advanced high-throughput screening systems, Codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. Since 2002, Codexis in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough developments in pharmaceuticals, biotherapeutics, food & beverage, and a wide range of other industries.

keywords:Biotechnology,E-Commerce,Food & Beverages,Healthcare,Pharmaceuticals

$162M

Total Funding

267

Number of Employees

$101.3M

Revenue (est)

-21%

Employee Growth %

$1.7B

Valuation

N/A

Accelerator

Codexis News

2022-04-20 - Codexis (CDXS) to Release Earnings on Thursday

Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Codexis has set its FY 2022 guidance at EPS.Parties that...

2022-04-13 - Codexis and seqWell Announce Strategic Investment and ...

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance...

2022-04-06 - Codexis and Molecular Assemblies Announce Results of First ...

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance...

2019-06-21 - Codexis Receives $50M Investment from Casdin Capital

Codexis, Inc. (Nasdaq: CDXS), a Redwood City, Calif.-based synthetic biology company, received a $50 million investment from Casdin Capital, LLC. Casdin, a New York City-based life science-focused investment firm, has invested through the purchase of shares of Codexis’ common stock in a private ...

2010-04-22 - Biofuel maker Codexis IPOs — but for less than hoped

Less than six months after filing to go public, Codexis, one of several makers of microbes and catalysts used to generate green fuels and chemicals, debuted on the Nasdaq this morning under the symbol CDXS. But the news is bittersweet for the cleantech sector. Yes, the company made it to market ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$43M27647%$350M
#2
$61.2M279-3%$96.3M
#3
$7.5M28051%N/A
#4
$42.9M28518%$45M
#5
$93.2M28925%$135.1M

Codexis Funding

DateAmountRoundLead InvestorsReference
2002-10-07$25.0MPrivate PlacementCMEA Ventures, Pequot VenturesArticle
2004-07-28$10.0MUndisclosedPfizerArticle
2006-08-25$37.0MDBio*One Capital Pte LtdArticle
2017-04-10$25.3MUndisclosedJefferies LLCArticle